H
Heather Ogana
Researcher at University of Southern California
Publications - 22
Citations - 225
Heather Ogana is an academic researcher from University of Southern California. The author has contributed to research in topics: Integrin & Leukemia. The author has an hindex of 6, co-authored 16 publications receiving 93 citations. Previous affiliations of Heather Ogana include Children's Hospital Los Angeles.
Papers
More filters
Journal ArticleDOI
Characterizing the Motility of Chemotherapeutics-Treated Acute Lymphoblastic Leukemia Cells by Time-Lapse Imaging.
Hsiao-Chuan Liu,Eun Ji Gang,Hye Na Kim,Yongsheng Ruan,Heather Ogana,Zesheng Wan,Halvard Bonig,Halvard Bonig,K. Kirk Shung,Yong-Mi Kim +9 more
TL;DR: The physical properties of the movements of chemoresistant B-ALL cells are explored and a potential link to integrins is highlighted, which could allow the metastasis of solid tumor cells and the migration of leukemia cells.
Journal ArticleDOI
Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia
Yongsheng Ruan,Yongsheng Ruan,Hye Na Kim,Heather Ogana,Zesheng Wan,Samantha Hurwitz,Cydney Nichols,Nour Abdel-Azim,Ariana Coba,Seyoung Seo,Yong-Hwee Eddie Loh,Eun Ji Gang,Hisham Abdel-Azim,Chih-Lin Hsieh,Michael R. Lieber,Chintan Parekh,Dhananjay Pal,Deepa Bhojwani,Donald L. Durden,Yong-Mi Kim +19 more
TL;DR: In this paper, a small molecule inhibitor called SF2535 was used to specifically target the PI3Kδ isoform and BRD4 in refractory or relapsed B-ALL.
Patent
Heavy chain antibodies binding to cd22
Shelley Force Aldred,Van Schooten Wim,Heather Ogana,Laura Davison,Harris Katherine,Udaya Rangaswamy,Nathan D. Trinklein +6 more
TL;DR: In this paper, the use of anti-CD22 heavy chain antibodies (e.g., UniAbs TM ) along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies and their use to treat B cell disorders that are characterized by the expression of CD22 are discussed.
Journal ArticleDOI
TBL1 Inhibitor, Tegavivint, Supresses Cell Survival and Promotes Sensitivity to Chemotherapy in ALL and AML
TL;DR: Tegavivint as discussed by the authors , a small molecule inhibitor of Wnt-ß-catenin signaling, binds to transducin ß-like protein 1 (TBL1) preventing the binding of TBL1 to β-Catenin.
Journal ArticleDOI
Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia
Heather Ogana,Samantha Hurwitz,Chih-Lin Hsieh,Huimin Geng,Markus Müschen,Deepa Bhojwani,Mark A. Wolf,James LaRocque,Michael R. Lieber,Yong Mi Kim +9 more
TL;DR: Artemis is a key endonuclease in V(D)J recombination and nonhomologous end joining (NHEJ) of DNA double-strand break (DSB) repair as mentioned in this paper .